Skip to content

Potential of intra-vitreal administration of ranibizumab in the treatment of retinopathy of prematurity (ROP)

Researchers based at the Department of Ophthalmology, Asociación para Evitar la Ceguera en Mexico, Hospital “Luis Sanchez Bulnes” I.A.P., Mexico and the Department of Ophthalmology at the Denver Health Medical Center, Colorado have published results from a small clinical study suggesting that intravitreal ranibizumab injections for ROP may preserve ocular outcome and inhibit neovascularisation. The researchers plan to conduct further large-scale studies to address long-term safety and efficacy in the treatment of ROP.